Clinical Trials
Page 5 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
LARA Phase 2 trial published in The Lancet Oncology demonstrates promising clinical activity of pembrolizumab plus lenvatinib for recurrent clear cell cancers.
Roche's Gazyva Receives FDA Acceptance for Lupus Treatment Following Positive Phase III Trial Results
FDA accepts Roche's supplemental application for Gazyva (obinutuzumab) in systemic lupus erythematosus based on positive ALLEGORY study results.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in TNBC preclinical studies.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in preclinical cancer studies.
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial
SAB-142 preserved C-peptide in all 4 Type 1 diabetes patients, with 3 showing super responder profiles and improved glycemic control in Phase 1 trial.
Boston Scientific Reports Strong Q1 2026 Growth with 10.9% US Sales Increase and Clinical Trial Breakthroughs
Boston Scientific delivers robust Q1 2026 performance with double-digit growth across all regions and presents breakthrough clinical trial data at major conference.
CervoMed's Neflamapimod Shows Brain Volume Increase in Dementia with Lewy Bodies Trial at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume and connectivity in DLB patients, suggesting potential disease reversal in early stages.
CervoMed's Neflamapimod Shows Brain Volume Improvements in Dementia with Lewy Bodies at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume in DLB patients, suggesting potential disease reversal in early neurodegenerative stages.
Celerion Secures Majority Investment from THL Partners to Expand Clinical Research Services
Clinical research organization Celerion announces majority investment from THL Partners to accelerate growth in drug development services and bioanalytical capabilities.
Veristat Acquires Certara's Regulatory Writing Business to Expand European Market Services
Veristat announces acquisition of Certara's regulatory and medical writing division to enhance clinical trial services for companies entering European markets.
Polycythemia Vera Market Transformation: 9 Companies Including Protagonist Therapeutics with Rusfertide to Enter by 2036
Nine pharmaceutical companies are advancing polycythemia vera treatments through clinical trials, with Protagonist Therapeutics' rusfertide leading market expansion by 2036.
Kelun-Biotech's Sac-TMT Cancer Drug Selected for Three ASCO 2026 Oral Presentations
Kelun-Biotech announces three clinical studies of sac-TMT selected for oral presentations at ASCO 2026, highlighting progress in cancer treatment.